All In Biotech

NDA 216986 · Guerbet

Elucirem

Gadopiclenol · Intravenous

NovelPriority review

CDER novel approval, Sep 21, 2022: To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 21, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

21

6 Phase 3, 5 recruiting

FAERS reports

278

100 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Vueway is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of Vueway in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m 2 ), or Acute kidney injury. Screen...

What it is approved for

From the label in effect Apr 3, 2026.

Vueway ® is indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) Vueway is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: the central nervous system (brain, spine, and associated tissues) the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) ( 1 )

Mechanism: Gadopiclenol is a paramagnetic molecule (macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • ELUCIREM · GADOPICLENOL 24.255GM/50ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ELUCIREM · GADOPICLENOL 7.2765GM/15ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ELUCIREM · GADOPICLENOL 3.63825GM/7.5ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ELUCIREM · GADOPICLENOL 48.51GM/100ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ELUCIREM · GADOPICLENOL 14.553GM/30ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ELUCIREM · GADOPICLENOL 4.851GM/10ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ELUCIREM · GADOPICLENOL 1.4553GM/3ML (485.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Gadopiclenol" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urticaria64
  • pruritus45
  • nausea42
  • vomiting38
  • rash28
  • erythema20
  • anaphylactic reaction17
  • dyspnoea17
  • hypersensitivity16
  • dizziness15
  • headache12
  • paraesthesia11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202312
202447
2025121
202698

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Elucirem* (Gadopiclenol*) · HCPCS A9573

2024 spending

$1.2M

Beneficiaries

22,982

25,728 claims

Per beneficiary

$51

2024 ASP limit $4.40 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$123,883
2024$1,173,443

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Guerbet

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.